KYTHERA Biopharmaceuticals Announces Presentation of Phase 2 Data on Novel Fat Reduction Drug at ASDS Meeting.MEDIA ADVISORY from KYTHERA Biopharmaceuticals: [TABLE OMITTED] About ATX-101 ATX-101 is a first-in-class injectable in·ject·a·ble adj. Capable of being injected. Used of a drug. n. A drug or medicine that can be injected. drug being studied for the reduction of small volumes of fat. It is based on an endogenous endogenous /en·dog·e·nous/ (en-doj´e-nus) produced within or caused by factors within the organism. en·dog·e·nous adj. 1. Originating or produced within an organism, tissue, or cell. compound with unique features including selectivity for adipocytes and rapid clearance. ATX-101 clinical research is focused on reduction of localized fat deposits, including submental fat. KYTHERA has completed two randomized ran·dom·ize tr.v. ran·dom·ized, ran·dom·iz·ing, ran·dom·iz·es To make random in arrangement, especially in order to control the variables in an experiment. , double-blind, placebo-controlled, Phase 2 studies with ATX-101 in the reduction of submental fat and two Phase 1 pharmacokinetic and histology histology (hĭstŏl`əjē), study of the groups of specialized cells called tissues that are found in most multicellular plants and animals. studies. About KYTHERA Biopharmaceuticals KYTHERA is a privately-held biopharmaceutical company that applies the tools of biotechnology to develop innovative prescription therapeutics for aesthetic medicine. KYTHERA has active programs in adipolysis (ATX-101), facial contouring (ATX-104) and pigmentation pigmentation, name for the coloring matter found in certain plant and animal cells and for the color produced thereby. Pigmentation occurs in nearly all living organisms. modulation (ATX-202). For more information about KYTHERA, please visit the company's Web site at www.kytherabiopharma.com. Data slides highlighting these results will be available online at http://www.kytherabiopharma.com/atx101.html on October 2, 2009 following the live presentation. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion